Akshat Jain: The First CRISPR-Cas9 Gene Therapy Approved for Children as Young as 2 with SCD
Akshat Jain, Hematology Pediatric Workforce Task Force at American Society of Hematology, shared a post on LinkedIn:
“Exciting milestone in pediatric hematology!
The U.S. FDA has granted a supplemental approval for Casgevy (exagamglogene autotemcel) — the first CRISPR-Cas9 gene therapy now available for children as young as 2 years old with sickle cell disease (SCD) experiencing recurrent vaso-occlusive crises (VOCs) or transfusion-dependent β-thalassemia (TDT).
Previously approved for patients aged 12 years and older, this expansion brings hope to younger patients and their families by enabling earlier intervention.
Clinical evidence from younger patients (extrapolated to patients aged 2 years and older) is comforting to justify the known and unknown cost of this platform for gene editing.
Earlier access can help reduce long-term organ damage, support better growth and development, and improve quality of life for children facing these burdensome conditions.
As a pediatric hematologist and advocate for rare blood disorders, I celebrate this label extension while emphasizing the need for equitable global access, especially in high-burden regions. Continued education, research, and support for patients remain essential.
Congratulations to Vertex Pharmaceuticals , the dedicated researchers, trial participants, and FDA teams for making this possible!”

Find more posts featuring Akshat Jain on Hemostasis Today.
-
Nov 21, 2026, 20:00Jeyda Star: The FAST Signs of Stroke and the Reality of Life Afterward
-
Nov 21, 2026, 19:59Daniel Lindholm: Women Showed the Largest Improvement in Stroke Risk Over Time in Heart Failure
-
Nov 21, 2026, 19:56Neil Arrowsmith: Raising Awareness of Pulmonary Embolism in Young People
-
Nov 21, 2026, 19:52Muhammad Zeeshan Jamal: Thrilled to Present Our Research on Intermediate-Risk Acute PE in Abu Dhabi
-
Nov 21, 2026, 19:50Mounisha Devireddy: Proud to Share Our Research on High-Risk PE in Pregnancy
-
Nov 21, 2026, 19:47Melissa Hollo: How Severe Anemia Increases the Odds of Acute HF During Pregnancy and Postpartum
-
Nov 21, 2026, 19:44Ashenafi Tazebew Amare: Building Sustainable Systems to Close the Anti-D Immunoglobulin Access Gap in LMICs
-
Nov 21, 2026, 19:43Sheharyar Raza: Interpreting Clotting Times Through Reptilase Time and Thrombin Time Assays
-
Nov 21, 2026, 19:42Minoo Ahmadinejad: Serving on the ISTH 2027 Scientific Theme Committee for Women’s Health